Talk:Corvadt/@comment-82.43.176.25-20200928234019

GSK on Monday said it would pay £130m for the stake in CureVac. GSK will also make a separate payment of £104m that will fund research into CureVac’s development of messenger ribonucleic acid (mRNA) vaccines. CUREVAC